MD-711 Phase 2/3 Study in PAH
Phase 2
Completed
- Conditions
- Pulmonary arterial hypertension
- Registration Number
- JPRN-jRCT2080224582
- Lead Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Group 1 under the updated clinical classification of pulmonary hypertension (5th World Symposium on Pulmonary Hypertension in Nice 2013)
Exclusion Criteria
Patients who have any of the diseases which are included in the Groups 2 to 5 under the updated clinical classification of pulmonary hypertension
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method efficacy<br>Rate of change in PVRI
- Secondary Outcome Measures
Name Time Method safety<br>efficacy<br>pharmacokinetics<br>- Efficacy<br>Change in 6-minute walk distance<br>- Safety<br>Adverse Reactions<br>- Pharmacokinetics<br>Plasma levels of treprostinil